















Stabilis



Imatinib



Stability of pharmaceutical preparations

								
		1800 mg Glivec®	2-8°C		30 			4636
		Citric acid 600 mg Cola flavor 240 mg Sucralose 60 mg Purified water >> 60 mL						





















References

	Type	Publication
4636	Journal	Hinterlang M, Gendron A, Fleury F, Rieutord A, Vrana A , Schlatter J, Annereau M. Design and stability of pediatric oral formulation of imatinib J Oncol Pharm Practice 2022 ;



Dictionary

 Anticancer drug	 Oral solution
 Stability of pharmaceutical preparations	 Container
 Origine	 Excipient
 Temperature	 Storage
 Duration	 Biosimilar
 Conflicting data	 References
 Glass	 Tablets
 Protect from light	 Day
 References	 Dictionary